EUCTR2005-002371-33-DE
Active, not recruiting
Not Applicable
Finasterid-unterstützte Diagnostik des Prostatakarzinoms bei Patienten mit BPH
rologische Partnerschaft0 sitesDecember 27, 2005
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- rologische Partnerschaft
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- patients with elevated serum\-PSA value
- •\- Negative biopsy (min. sixfold), max. 2\-12 months prior to inclusion
- •\- Existence of enlargement of the prostate (\>25 ml)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •\- former or current use of 5\-alpha reductase inhibitors
- •\- proof of prostate cancer
- •\- acute prostatitis
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Dutasteride for biopsy-negative benign prostate hyperplasia - effects on cancer detection and aging male symptomsbiopsy-negative benign prostate hyperplasiaJPRN-UMIN000005288Department of Urology, University of Tokyo Hospital40
Not yet recruiting
Phase 2
Diagnostic Performance of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Pre-operative Lymph Node Assessment in Intermediate and High-risk Nonmetastasic Prostate Cancer2024-516319-25-00Centre Hospitalier Regional Et Universitaire De Brest159
Recruiting
Not Applicable
Detection of clinically significant prostate cancer with MRI-TRUS fusion image-guided biopsy: comparison of the evaluation system (PI-RADS category vs. PI-RADS + US evalutaion)Suspected prostate cancerJPRN-UMIN000050631Tokai University80
Recruiting
Not Applicable
A decision aid for the treatment of Benign Prostatic HyperplasiaDA BPHNL-OMON27217200
Completed
Phase 2
Phase IIa Study of F-1311 in Patients with Prostate CancerProstate cancerJPRN-jRCT2080222723PDRadiopharma Inc.15